Standout Papers

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant c... 2018 2026 2020 2023 504
  1. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial (2018)
    Sibylle Loibl, Joyce O’Shaughnessy et al. The Lancet Oncology

Citation Impact

5 from Science/Nature 58 standout
Sub-graph 1 of 20

Citing Papers

Catalytic Asymmetric Construction of Chiral Polysubstituted 3-Azabicyclo[3.1.1]heptanes by Copper-Catalyzed Stereoselective Formal [4π+2σ] Cycloaddition
2024 Standout
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression
2024 Standout
2 intermediate papers

Works of José Ponce being referenced

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
2018 Standout

Author Peers

Author Oncology Surgery Molecular Biology Cancer Research Last Decade Papers Cites
José Ponce 628 213 251 292 23 935
Hai Hai 18 18 157 7 203 908
Lihua Mao 1 2 35 24 44 1.1k
Richard Donato 1 38 1.3k
M. K. W. Lo 60 24 22 4 9 328
Kyle R. Taylor 1 6 24 245

All Works

Loading papers...

Rankless by CCL
2026